Humana posted first-quarter 2026 earnings that beat Wall Street estimates. However, declining Medicare Advantage star ratings are squeezing federal bonus payments, and investors are not satisfied. Shares dropped more than 6% after the company left its full-year adjusted profit target unchanged and cut its reported earnings outlook. The results highlight a growing challenge for one of America’s largest health insurers.
Q1 2026 Earnings at a Glance
Revenue Growth Cannot Mask Profit Pressure
Humana reported strong revenue growth for the quarter. The company brought in $39.6 billion in revenue, up from $32.1 billion in the same period last year — results that surpassed Wall Street forecasts. Insurance segment revenues also climbed sharply, growing to $38.06 billion from $30.95 billion a year earlier, driven by membership growth across Medicare businesses. Premiums increased to $37.71 billion from $30.51 billion.
However, net profit told a different story. Net income attributable to Humana declined to $1.19 billion, or $9.83 per share, from $1.24 billion a year earlier. On an adjusted basis, Humana posted adjusted EPS of $10.31, above the analyst consensus estimate of $10.19.
Guidance Signals a Difficult Year Ahead
Humana held its annual adjusted profit forecast at a minimum of $9 per share, unchanged from previous guidance. Notably, it lowered its reported profit forecast to at least $8.36 from a prior estimate of at least $8.89, citing the impact of star ratings issued by the Medicare agency. By comparison, Humana’s adjusted EPS stood at $17.14 in 2025 — making the 2026 adjusted target a steep drop in absolute terms.
How Medicare Star Ratings Work
The Federal Scorecard That Drives Insurer Revenue
Medicare Advantage star ratings are quality scores assigned annually by the Centers for Medicare and Medicaid Services. The star rating system measures plan quality on a scale from one to five stars. Higher stars give insurers favorable positioning in the program in addition to lucrative bonuses.
Why Four Stars Is the Critical Threshold
Plans that receive an overall rating of four stars or higher receive higher bonus payments. Higher scores also result in larger rebates if plans submit bids below the CMS benchmark for the coming year. Falling below this threshold, therefore, directly reduces both bonus income and competitive bidding power. For large insurers like Humana, even a partial dip in star-rated membership can translate into billions of dollars in lost revenue.
The Star Ratings Collapse Explained
A Dramatic Decline in Rated Membership
Humana’s star ratings problem has been building since 2024. Members enrolled in four-star plans or above reached 1.6 million, or just 25% of all members for 2025 — down sharply from a 94% enrollment rate in 2024. This near-total reversal of rated membership created a significant financial headwind that flows directly into 2026 bonus payments.
The Largest Contract Took a Heavy Hit
One of Humana’s largest contracts, covering about 45% of its Medicare Advantage members, dropped an entire point — from 4.5 to 3.5 stars. That single-contract decline was enough to remove millions of members from bonus-eligible plans almost overnight. Consequently, Humana’s federal bonus payments for 2026 are materially smaller than in prior years.
The Financial Impact on 2026 Bonuses
Declining Medicare Advantage star ratings for 2026 are pressuring bonus payments and bottom-line results. Reduced ratings translate to smaller bonus payments, and the insurer has been communicating this obstacle for several quarters. Furthermore, the year-over-year increase in the GAAP consolidated benefit ratio primarily reflected the Bonus Year 2026 star ratings revenue headwind, along with the effect of individual Medicare Advantage membership growth during the most recent Annual Election Period.
Legal Battle and Court Defeat
Humana Fought the Ratings — and Lost
Humana did not accept the star ratings downgrade quietly. The company filed a lawsuit seeking to set aside and vacate the 2025 star ratings of its Medicare Advantage plans. On October 14, 2025, the court issued a decision rejecting Humana’s challenge. Although the company filed an appeal, a Texas judge ultimately ruled in favor of a government motion to dismiss the case, allowing the downgrade of Humana’s Medicare quality ratings to stand. Humana shares dropped as much as 7.5% before paring losses following that ruling.
Appeals Continue With No Guaranteed Outcome
There can be no assurances the company will be successful in maintaining or improving its star ratings in future years. Meanwhile, Humana is exploring all available options to mitigate the expected 2026 revenue headwind related to its 2025 star ratings in the event its challenges to the results are unsuccessful.
What Analysts and Investors Are Saying
An Earnings Beat That Did Not Satisfy Markets
Humana posted adjusted earnings per share of $10.31 for the first quarter, edging past the analyst consensus estimate of $10.19. The beat was driven primarily by medical costs coming in below the company’s own projections — a meaningful positive signal in an industry where cost management has become the defining challenge of the past three years. Yet investors focused on the unchanged guidance and cut reported earnings target, sending shares lower.
The Benefit Ratio Offered a Bright Spot
The Q1 2026 Insurance segment GAAP benefit ratio came in at 89.4%, slightly favorable to management’s guidance of just under 90%. A lower benefit ratio indicates better cost efficiency, and Humana’s result pointed to solid medical cost discipline. Despite this, the market’s reaction reflected a specific disappointment: investors had expected a strong quarterly start to translate into upgraded guidance, and it did not.
The Widening Reimbursement Gap
Management emphasized that the differential between the company’s healthcare spending and government reimbursement rates has expanded year-over-year. This gap between what Humana spends on member care and what CMS pays back is a systemic challenge across the Medicare Advantage industry — and it shows no immediate signs of narrowing.
Leadership Changes at Humana
An Executive Transition Adds Uncertainty
Beyond the financial headlines, Humana is also navigating a senior leadership transition. The company confirmed that George Renaudin, Insurance Segment President, will retire effective June 29. Aaron Martin, currently President of Medicare Advantage, will begin leading day-to-day management of the Insurance Segment and will formally assume the role of Insurance Segment President following Renaudin’s retirement. Additionally, John Barger will begin leading Medicare Advantage operations immediately and will formally assume the role of President of Medicare Advantage upon Renaudin’s retirement.
The Road Ahead for Humana
Membership Growth Offers a Counterweight
Despite the profit pressure, Humana’s membership trajectory remains a positive indicator. The company anticipates full-year 2026 individual Medicare Advantage membership growth of approximately 25% over 2025, driven by new sales and improved retention from its customer-led benefit strategy and changes to its customer service approach. Growth at this scale could help offset some of the bonus payment losses — but only if cost trends remain manageable.
Restructuring Costs Add to Near-Term Headwinds
The downward revision to reported earnings guidance also accounts for expenses tied to a multiyear restructuring initiative, encompassing severance payments, asset write-downs, and external consulting fees. These near-term costs are intended to position Humana more efficiently for future years, though they weigh on 2026 profitability.
A Critical Test for Medicare Advantage Insurers
Humana’s situation reflects a broader industry stress point. Medicare Advantage insurers are caught between rising medical utilization, fixed government reimbursements, and a star ratings system that can dramatically shift bonus income from one year to the next. Humana’s ability to recover its star ratings — and restore bonus payment levels — will determine much of its financial trajectory through 2027 and beyond.
